Eton Pharmaceuticals Net Worth
Eton Pharmaceuticals Net Worth Breakdown | ETON |
Eton Pharmaceuticals Net Worth Analysis
Eton Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Eton Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Eton Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Eton Pharmaceuticals' net worth analysis. One common approach is to calculate Eton Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Eton Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Eton Pharmaceuticals' net worth. This approach calculates the present value of Eton Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Eton Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Eton Pharmaceuticals' net worth. This involves comparing Eton Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Eton Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Eton Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Eton Pharmaceuticals' net worth research are outlined below:
| Eton Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 39.01 M. Net Loss for the year was (3.82 M) with profit before overhead, payroll, taxes, and interest of 36.91 M. | |
| Eton Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| About 62.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Street Watch Will Eton Pharmaceuticals Inc. stock deliver shareholder value - 2025 Geopolitical Influence Verified Short-Term Plans - Fundao Cultural do Par |
Eton Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Eton Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Eton Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Eton Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eton Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eton Pharmaceuticals backward and forwards among themselves. Eton Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Eton Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Thompson, Siegel & Walmsley Llc | 2025-06-30 | 381.3 K | State Street Corp | 2025-06-30 | 323.2 K | Soleus Capital Management, L.p. | 2025-06-30 | 285 K | Northern Trust Corp | 2025-06-30 | 262.2 K | Jpmorgan Chase & Co | 2025-06-30 | 242.6 K | Connor Clark & Lunn Inv Mgmt Ltd | 2025-06-30 | 222.1 K | Two Sigma Investments Llc | 2025-06-30 | 214.6 K | Ubs Group Ag | 2025-06-30 | 212.5 K | Aristides Capital Llc | 2025-06-30 | 167.6 K | Opaleye Management Inc | 2025-06-30 | 2.9 M | Ecor1 Capital, Llc | 2025-06-30 | 2 M |
Follow Eton Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 482.98 M.Market Cap |
|
Project Eton Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.09) | (0.10) | |
| Return On Capital Employed | (0.05) | (0.05) | |
| Return On Assets | (0.05) | (0.05) | |
| Return On Equity | (0.16) | (0.16) |
When accessing Eton Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Eton Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Eton Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Eton Pharmaceuticals' management efficiency
Eton Pharmaceuticals has return on total asset (ROA) of 0.0183 % which means that it generated a profit of $0.0183 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2206) %, meaning that it created substantial loss on money invested by shareholders. Eton Pharmaceuticals' management efficiency ratios could be used to measure how well Eton Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of November 2025, Return On Tangible Assets is likely to drop to -0.1. In addition to that, Return On Capital Employed is likely to drop to -0.05. At this time, Eton Pharmaceuticals' Fixed Asset Turnover is very stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.94 | 1.22 | |
| Tangible Book Value Per Share | (0.40) | (0.38) | |
| Enterprise Value Over EBITDA | (248.04) | (235.64) | |
| Price Book Value Ratio | 14.12 | 14.83 | |
| Enterprise Value Multiple | (248.04) | (235.64) | |
| Price Fair Value | 14.12 | 14.83 | |
| Enterprise Value | 55 M | 71.5 M |
The management team at Eton Pharmaceuticals has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Enterprise Value Revenue 9.2174 | Revenue | Quarterly Revenue Growth 1.086 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eton Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eton Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eton Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Eton Pharmaceuticals Corporate Filings
| 30th of October 2025 Other Reports | ViewVerify | |
F4 | 20th of August 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 7th of August 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 2nd of May 2025 An amendment to a previously filed Form 8-K | ViewVerify |
Eton Pharmaceuticals Earnings per Share Projection vs Actual
Eton Pharmaceuticals Corporate Management
| Danka Radosavljevic | Executive Operations | Profile | |
| James CPA | Treasurer CFO | Profile | |
| Kevin Guthrie | Executive Operations | Profile | |
| Scott Grossenbach | Senior Operations | Profile | |
| Ingrid Hoos | Senior Affairs | Profile | |
| Ipek ErdoganTrinkaus | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eton Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eton Pharmaceuticals. If investors know Eton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eton Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Earnings Share (0.15) | Revenue Per Share | Quarterly Revenue Growth 1.086 | Return On Assets |
The market value of Eton Pharmaceuticals is measured differently than its book value, which is the value of Eton that is recorded on the company's balance sheet. Investors also form their own opinion of Eton Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eton Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eton Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eton Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eton Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eton Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eton Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.